FDA

A total of “1.7 million Americans will receive a new cancer diagnosis this year,” announced Frederick Ryan , President, and CEO of The Washington Post , in his opening remarks for the Post’s Chasing Cancer event earlier this month. Sponsored by Tesaro and the George Washington Cancer Center, the event did not shy away from difficult topic matter. Still, there were bright spots. “Why does cancer seem to work better in terms of novel therapeutic discoveries than other areas?” Asked new Acting FDA Commissioner Ned Sharpless . He believes it’s in part because researchers have a “good biologic understanding of the problem,” something that may be lacking when it comes to other conditions. The “...
Dear Research Advocate, The House Labor-HHS Appropriations Subcommittee markup of Fiscal Year 2020 spending priorities on Tuesday featured lots of good news. You can watch the subcommittee’s deliberations here and find draft text of the bill here . The next stop is consideration by the full Appropriations Committee on May 8, 2019. Some highlights: $41.1 billion for the National Institutes of Health, an increase of $2 billion above last year; $8.3 billion for the Centers for Disease Control and Prevention, $921 million above the 2019 enacted level, including new funding for efforts to support modernization of public health data systems (for example, to track and prevent the spread of...
Dear Research Advocate, I am very pleased to announce that Research!America’s 2020 Advocacy Awards nominations are now open! Act now to nominate those you want to recognize for outstanding advocacy leadership on behalf of scientific, medical, or public health research. The awards will be presented at our dinner next March. When members of Congress return to Washington, D.C. next week, the House will begin considering Fiscal Year (FY) 2020 appropriations bills, with the Labor-HHS Subcommittee scheduled to mark up their bill on April 30. Trust for America’s Health (TFAH) has released a new report explaining why our nation needs a well-resourced public health system (which pivots on a well-...
Dear Research Advocate: As you know, there has been a cease fire in the shutdown and people are back to work, at least for now. Over the next two weeks, members of Congress will attempt to resolve the stalemate over funding for the President’s border wall, packaging it with the seven remaining FY 2019 spending bills, which include funding for the Food and Drug Administration (FDA) and the National Science Foundation (NSF). I am feeling optimistic about a deal being struck, not least because Sen. Richard Shelby (R-AL), Chairman of the Senate Appropriations Committee, and Representative Nita Lowey (D-NY), Chairwoman of the House Appropriations Committee, are leading the congressional...
Dear Research Advocate, The partial government shutdown continues, now at day 27. There are too many furloughed workers struggling to make ends meet, our nation’s parks and monuments are being ruined, research support by NSF has been put on hold, and drug approvals have slowed at FDA. For a run-down on the broadscale impact, see this USA Today article quoting ASBMB’s Ben Corb, and for a closer look at the toll the shutdown is taking on research, check out this article discussing the impact at the University of Wisconsin, emblematic of so many campuses nationwide. As a temporary patch, agency leaders have called back thousands of employees to work without pay. At the FDA, Commissioner Scott...
Dear Research Advocate: The government remains in a partial shutdown that began on December 22, taking a mounting toll on 800,000 federal workers, including those at FDA and NSF. The Alliance for a Stronger FDA has put together a “ Shutdown Toolkit ” detailing how this ongoing impasse is affecting us all. In a similar vein, the Coalition for National Science Funding has been sharing stories on social media that focus on how the shutdown is impacting NSF-funded research and programs, stifling discovery and sending a message of ‘no public confidence’ to aspiring young scientists. Clearly, the effects of the shutdown on research are multiple, disruptive and counterproductive. This New York...
Dear Research Advocate: At our post-election briefing this morning at AAAS in Washington, DC, the discussion focused on opportunities for advocacy given the composition and characteristics of the new Congress, and the importance of building new champions from among the nearly 100 new members of Congress. Of note — at last count, there are seven science-trained new members, a very welcome development! There is no doubt that a divided Congress can cause gridlock, but inaction is not a foregone conclusion, as was emphasized by our Chair, the Hon. Michael N. Castle. There are important, science-relevant issues, such as infrastructure, STEM education, and the opioid crisis, that both parties...
Dear Research Advocate: Earlier today, Rob Smith and Kim Monk of Capital Alpha Partners, and Pete Kirkham of Red Maple Consulting joined Research!America alliance members to discuss the near and mid-term outlook for congressional action on drug pricing, the state of play on appropriations, and other research-relevant issues. Although our speakers noted that much can change in the final week before the election, there were several key takeaways. First, it’s safe to say that the uncertainties surrounding the election and the ongoing interest (both in Congress and the White House) in addressing rising healthcare costs means that drug pricing and issues related to the supply chain more...
To Americans, there are few things more terrifying than going blind . Glaucoma is a particularly scary vision-stealing disease because without screening it offers no warning to those it strikes, causing significant, irreversible vision loss before a patient notices something is wrong. But in January, in honor of Glaucoma Awareness Month, the vision-research community reflects on the past year’s progress toward managing this challenging disease. As with all diseases, progress is dependent on research. First, it looks into understanding what causes the condition, and then into therapies that prevent, treat or cure it. Glaucoma research, spanning decades, has successfully identified what...
Research into the development of Ebola vaccines, efforts to address opioid use among women, infectious diseases and a record number of novel drug approvals are among the many examples of federal health agencies making tremendous strides in 2017 to address complex and deadly health threats. The agencies highlighted their achievements in year-end articles, videos and reports on their websites. The National Institutes of Health (NIH) described progress with two Ebola vaccines and a bionic pancreas to better treat type 1 diabetes in addition to other clinical advances. The NIH also supported the work of three recipients of the Nobel Prize in Physiology or Medicine and one recipient of the Nobel...

Pages

Sidebar Quote

We have health challenges in this country that science will provide answers for if given the chance and we haven't given science that opportunity
Mary Woolley, President and CEO, Research!America